Patents by Inventor Tetsuji Yamaoka

Tetsuji Yamaoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11253626
    Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 22, 2022
    Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.
    Inventors: Tetsuji Yamaoka, Maria Chiara Munisso, Atsushi Mahara, Takashi Yamamoto
  • Publication number: 20190365944
    Abstract: Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 5, 2019
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JMS CO., LTD.
    Inventors: Tetsuji YAMAOKA, Maria MUNISSO, Atsushi MAHARA, Takashi YAMAMOTO
  • Patent number: 10351600
    Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: July 16, 2019
    Assignees: National Cerebral and Cardiovascular Center, JMS Co., Ltd.
    Inventors: Tetsuji Yamaoka, Sachiro Kakinoki, Shunsuke Baba, Yoshiya Hashimoto
  • Publication number: 20170327539
    Abstract: A peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Inventors: Tetsuji YAMAOKA, Sachiro KAKINOKI, Shunsuke BABA, Yoshiya HASHIMOTO
  • Patent number: 9642695
    Abstract: In order to provide an artificial blood vessel that can prevent formation of a thrombus and a method for producing the artificial blood vessel, an artificial blood vessel is used (i) in which a peptide including a specific amino acid sequence has been added to an extracellular matrix obtained from a bio-derived vascular tissue and (ii) whose lumen has a cross sectional diameter of 4 mm or less.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: May 9, 2017
    Assignee: JMS CO., LTD.
    Inventors: Tetsuji Yamaoka, Atsushi Mahara
  • Publication number: 20160137694
    Abstract: Provided are a peptide that enables surface treatment of a scaffold for tissue repair that makes it possible to accelerate the repair of living tissue without using a material that negatively affects the repair of living tissue, a complex containing this peptide, a scaffold for tissue repair surface treated using this peptide or this complex, a surface treatment method for a scaffold for tissue repair using this peptide or this complex, and a treatment solution or set of treatment solutions to be used in this surface treatment method. Surface treatment of a scaffold for tissue repair is conducted by combining glycosaminoglycan and a peptide containing adhesive sites and basic sites each comprising predetermined amino acid residues.
    Type: Application
    Filed: April 25, 2014
    Publication date: May 19, 2016
    Inventors: Tetsuji YAMAOKA, Sachiro KAKINOKI, Shunsuke BABA, Yoshiya HASHIMOTO
  • Publication number: 20150272719
    Abstract: In order to provide an artificial blood vessel that can prevent formation of a thrombus and a method for producing the artificial blood vessel, an artificial blood vessel is used (i) in which a peptide including a specific amino acid sequence has been added to an extracellular matrix obtained from a bio-derived vascular tissue and (ii) whose lumen has a cross sectional diameter of 4 mm or less.
    Type: Application
    Filed: September 5, 2013
    Publication date: October 1, 2015
    Inventors: Tetsuji Yamaoka, Atsushi Mahara
  • Patent number: 9127280
    Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: September 8, 2015
    Assignees: Osaka University, National Cerebral and Cardiovascular Center, Tokyo University of Science Education Foundation Administrative Organization
    Inventors: Satoshi Obika, Takeshi Imanishi, Tsuyoshi Yamamoto, Keisuke Narukawa, Mariko Shiba, Tetsuji Yamaoka, Hidetaka Torigoe, Atsushi Yamashita, Yoichi Tachibana, Sachiro Kakinoki, Kiyomi Sasaki
  • Patent number: 8871242
    Abstract: A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: October 28, 2014
    Assignee: National Cerebral and Cardiovascular Center
    Inventors: Tetsuji Yamaoka, Satoshi Kato, Atsushi Kasai, Sachiro Kakinoki
  • Patent number: 8834887
    Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: September 16, 2014
    Assignees: National Cerebral and Cardiovascular Center, Kowa Co., Ltd.
    Inventors: Tetsuji Yamaoka, Mariko Shiba, Atsushi Mahara, Yoshihito Kato
  • Publication number: 20130172402
    Abstract: An object of the present invention is to provide an oligonucleotide useful as a therapeutic agent for dyslipidemia that has excellent binding affinity to the PCSK9 gene as well as stability and safety. The oligonucleotide of the present invention contains a sugar-modified nucleoside, the sugar-modified nucleoside has a bridging structure between 4?-position and 2?-position, and the oligonucleotide can bind to the human PCSK9 gene. Also, the present invention provides a therapeutic agent for dyslipidemia containing the oligonucleotide as an active ingredient, and the therapeutic agent preferably contains a bioabsorbable material as a carrier. The bioabsorbable material is preferably atelocollagen or peptide gel.
    Type: Application
    Filed: August 31, 2011
    Publication date: July 4, 2013
    Applicants: Osaka University, Tokyo University of Science Educational Foundation Administrative Organization, National Cerebral and Cardiovascular Center
    Inventors: Satoshi Obika, Takeshi Imanishi, Tsuyoshi Yamamoto, Keisuke Narukawa, Mariko Shiba, Tetsuji Yamaoka, Hidetaka Torigoe, Atsushi Yamashita, Yoichi Tachibana, Sachiro Kakinoki, Kiyomi Sasaki
  • Publication number: 20100209441
    Abstract: To provide a drug for actively metabolizing or excreting a pathogen occurring in vivo. The present invention is directed to a compound which is formed of (A) an adsorbent for a pathogen occurring in the blood or lymph, and (B) a ligand which is specific to an organ or cells capable of metabolizing or excreting the pathogen and which is bonded to the adsorbent via a linker or with no linker, and to a drug containing the same.
    Type: Application
    Filed: September 25, 2008
    Publication date: August 19, 2010
    Applicants: JAPAN AS REP. BY THE PRES. OF NAT'L. CARDIO CENTR, KOWA CO., LTD.
    Inventors: Tetsuji Yamaoka, Mariko Shiba, Atsushi Mahara, Yoshihito Kato
  • Publication number: 20100030325
    Abstract: A blood anticoagulant material is provided which has high expandability, reduced influence on living bodies, and can efficiently prevent blood coagulation. A multiblock copolymer having at least a structural unit represented by Formula (1), a structural unit represented by Formula (2), and a structural unit represented by Formula (3) is used: wherein, R1, R2, and R3 in Formulas (1) to (3) each independently represent a divalent organic group, and m and n each independently represent an integer of 2 to 5000.
    Type: Application
    Filed: November 16, 2007
    Publication date: February 4, 2010
    Applicants: Japan as Rep. by Pres. of Nat. Cardiovascular Ctr., MITSUBISHI CHEMICAL CORPORATION
    Inventors: Tetsuji Yamaoka, Satoshi Kato, Atsushi Kasai, Sachiro Kakinoki
  • Patent number: 7550512
    Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: June 23, 2009
    Assignees: Keio University, NOF Corporation
    Inventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka
  • Publication number: 20070059828
    Abstract: A carrier for nucleic acid molecule delivery formed from a saccharified copolymer comprising repeating unit (A) having a cationic group, saccharified repeating unit (B). There is further provided a carrier for nucleic acid molecule delivery formed from a saccharified copolymer comprising, in addition to the repeating units (A) and (B), repeating unit (C) having a hydrophobic substituent.
    Type: Application
    Filed: November 5, 2004
    Publication date: March 15, 2007
    Inventors: Tetsuji Yamaoka, Yutaka Tokiwa, Masaru Kitagawa
  • Publication number: 20050036973
    Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.
    Type: Application
    Filed: June 3, 2004
    Publication date: February 17, 2005
    Applicants: KEIO UNIVERSITY, NOF CORPORATION
    Inventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka
  • Publication number: 20040097659
    Abstract: The present invention provides a polyethylene glycol derivative having sugar residue-containing side chains and carboxyl group-containing side chains, and a method of preparing the same. The present invention also provides a carrier for drug delivery systems and a carrier for gene transfer, both comprising the polyethylene glycol derivative.
    Type: Application
    Filed: August 27, 2003
    Publication date: May 20, 2004
    Inventors: Toshinori Sato, Yoshiyuki Koyama, Tetsuji Yamaoka